Venus Medtech (Hangzhou), Inc. Class H (VMTHF)
Venus Medtech (Hangzhou), Inc. Class H operates in the Medical - Specialties industry of the Healthcare sector, headquartered in Wanchai, WA, CN. The stock last traded at $0.42, up 0.00% on the session, giving a market capitalisation of $186.1M. On trailing twelve-month figures it carries a trailing P/E of -1.00, a net margin of -132.9%. Its beta of 1.15 implies it has historically moved more than the broad market.
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company's offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People's Republic of China.
Venus Medtech (Hangzhou), Inc. Class H is most often compared with the following Healthcare names: